Study in Hospitalized Patients<\/p>\n
Amparo Herna\u00b4ndez-Salazar,a Samuel Ponce-de-Leo\u00b4n Rosales,b Sigfrido Rangel-Frausto,b Background. Drug reactions are commonly present in the skin; however, their frequency Methods. A 10-month prospective cohort study including all hospitalized patients was Results. Thirty five drug reactions (prevalence of 0.7%) were seen among 4785 (2713 females, Conclusions. We have a low prevalence of drug reactions compared to data reported in Study in Hospitalized Patients Amparo Herna\u00b4ndez-Salazar,a Samuel Ponce-de-Leo\u00b4n Rosales,b Sigfrido Rangel-Frausto,b Elia Criollo,c Carla Archer-Dubon,a and Roc?\u00b4o Orozco-Topetea aDermatology Department, bSubdivision of Hospital Epidemiology and Patient Care Quality Control, cPharmacy Department, Instituto Nacional de Ciencias M\u00e9dicas y Nutrici\u00f3n, Salvador Zubira\u00b4n, Mexico City, Mexico Received for publication June 2, 2005; accepted March 20, 2006 (ARCMED-D-05-00211). Background. …<\/p>\n","protected":false},"author":16,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[8],"tags":[],"class_list":["post-40152","post","type-post","status-publish","format-standard","","category-articulos-cientificos"],"_links":{"self":[{"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/posts\/40152","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/users\/16"}],"replies":[{"embeddable":true,"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/comments?post=40152"}],"version-history":[{"count":0,"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/posts\/40152\/revisions"}],"wp:attachment":[{"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/media?parent=40152"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/categories?post=40152"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/tags?post=40152"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
\nElia Criollo,c Carla Archer-Dubon,a and Roc?\u00b4o Orozco-Topetea
\naDermatology Department, bSubdivision of Hospital Epidemiology and Patient Care Quality Control, cPharmacy Department,<\/span>
\n Instituto Nacional de Ciencias M\u00e9dicas y Nutrici\u00f3n, Salvador Zubira\u00b4n, Mexico City, Mexico<\/span>
\n Received for publication June 2, 2005; accepted March 20, 2006 (ARCMED-D-05-00211).<\/span><\/p>\n
\nin our setting is unknown.<\/p>\n
\ndesigned. Those with adverse cutaneous drug reactions (ACDR) were clinically identified.<\/p>\n
\n2072 males) discharged patients. According to Begaud\u2019s imputability criteria, the
\nreactions were most likely attributed to a drug in 4.87%, likely in 41.46% and possible in
\n53.65%. The most commonly seen dermatoses were morbilliform rash 51.2%, urticaria
\n12.2% and erythema multiforme 4.9%. Drugs most frequently associated with ACDR
\nwere amoxicillin clavulanate (8), amphotericin B (2) and metamizole (4). Expressed as
\nrisk by 1000 day-doses (Dd: the risk a patient has of developing an ACDR after receiving
\n1 day of treatment with the drug): amoxicillin clavulanate Dd 7.7, amphotericin B Dd 4.8
\nand metamizole Dd 3.7. Immunosuppressed patients were most frequently affected. Notably,
\npatients with systemic lupus erythematosus (SLE) had a 4.68 higher risk (CI 95%
\n1.794e12.186 p !0.001) of developing an ACDR. AIDS patients showed a risk of 8.68
\n(CI 95% 2.18e33.19 p !0.001). Non-Hodgkin\u2019s lymphoma patients also had an increased
\nrisk of developing an ACDR. Six of the 35 identified cases were patients who
\nhad been hospitalized due to a severe drug reaction (1.3\/1000 patients); one died from
\ncomplications directly related to the ACDR, representing a 16.6% mortality rate among
\nthose admitted for an ACDR and 0.02% among the global mortality.<\/p>\n
\nthe literature. Pharmacovigilance with special attention to immunosuppressed SLE or
\nAIDS patients is stressed. _ 2006 IMSS. Published by Elsevier Inc.<\/p>\n","protected":false},"excerpt":{"rendered":"